NASDAQ:APLS

Apellis Pharmaceuticals News Headlines

$64.90
+2.78 (+4.48 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.13
$64.98
50-Day Range
$40.90
$64.90
52-Week Range
$25.49
$64.98
Volume670,201 shs
Average Volume713,482 shs
Market Capitalization$5.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.48

Apellis Pharmaceuticals (NASDAQ APLS) News Headlines Today

SourceHeadline
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High at $62.56Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High at $62.56
americanbankingnews.com - June 14 at 11:02 AM
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High at $59.57Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High at $59.57
americanbankingnews.com - June 8 at 12:34 PM
 Brokerages Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Announce -$1.70 EPS Brokerages Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Announce -$1.70 EPS
americanbankingnews.com - June 6 at 1:12 PM
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) VP Nicole D. Perry Sells 1,000 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS) VP Nicole D. Perry Sells 1,000 Shares
americanbankingnews.com - June 2 at 5:38 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High at $58.60Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High at $58.60
americanbankingnews.com - May 28 at 6:12 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.8% Higher Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.8% Higher
americanbankingnews.com - May 27 at 3:38 PM
Apellis (APLS) Empaveli Succeeds in Treatment-Naive PNH StudyApellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
finance.yahoo.com - May 26 at 12:17 PM
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI(TM) (pegcetacoplan) in Treatment-naive Patients with PNHApellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI(TM) (pegcetacoplan) in Treatment-naive Patients with PNH
marketwatch.com - May 26 at 2:16 AM
First Week of APLS January 2022 Options TradingFirst Week of APLS January 2022 Options Trading
nasdaq.com - May 21 at 2:04 PM
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop Sells 149,488 SharesApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop Sells 149,488 Shares
americanbankingnews.com - May 20 at 7:20 PM
Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at UBS GroupApellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at UBS Group
americanbankingnews.com - May 20 at 5:11 PM
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
finance.yahoo.com - May 19 at 1:33 PM
Top Biotech Stocks To Buy Right Now? 3 For Your WatchlistTop Biotech Stocks To Buy Right Now? 3 For Your Watchlist
nasdaq.com - May 18 at 7:09 PM
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
finance.yahoo.com - May 14 at 7:23 PM
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This YearApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This Year
finance.yahoo.com - May 4 at 7:45 AM
Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?
finance.yahoo.com - May 1 at 9:37 AM
Apellis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call PresentationApellis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 30 at 4:50 PM
Apellis (APLS) Q1 Earnings Miss, Pegcetacoplan in FocusApellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
finance.yahoo.com - April 29 at 12:41 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 26 at 9:34 AM
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
finance.yahoo.com - April 21 at 8:15 AM
Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 12:32 PM
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic AtrophyApellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
finance.yahoo.com - March 10 at 9:31 AM
Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 PatientsApellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients
finance.yahoo.com - March 5 at 10:47 AM
Apellis Provides Update on APL-9 for Severe COVID-19Apellis Provides Update on APL-9 for Severe COVID-19
finance.yahoo.com - March 4 at 6:58 PM
Analyst Forecasts Just Became More Bearish On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Analyst Forecasts Just Became More Bearish On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
finance.yahoo.com - March 2 at 8:09 AM
Apellis Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationApellis Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 1:49 PM
APLS Feb 2021 40.000 putAPLS Feb 2021 40.000 put
ca.finance.yahoo.com - January 22 at 12:07 AM
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common StockApellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
finance.yahoo.com - January 7 at 8:44 AM
APLS Jan 2021 50.000 putAPLS Jan 2021 50.000 put
ca.finance.yahoo.com - December 25 at 10:23 PM
First Week of APLS February 2021 Options TradingFirst Week of APLS February 2021 Options Trading
nasdaq.com - December 18 at 2:45 PM
Apellis remains a top pick at Baird after AstraZeneca/Alexion dealApellis remains a top pick at Baird after AstraZeneca/Alexion deal
seekingalpha.com - December 16 at 12:53 AM
J&J (JNJ) Acquires Rights for Hemera Biosciences Gene TherapyJ&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy
msn.com - December 3 at 12:51 PM
Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx ConferenceApellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
finance.yahoo.com - November 30 at 9:12 AM
FDA accepts Apellis pegcetacoplan application for a rare blood disorderFDA accepts Apellis' pegcetacoplan application for a rare blood disorder
seekingalpha.com - November 16 at 8:41 AM
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNHApellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
finance.yahoo.com - November 16 at 8:41 AM
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 VirtualApellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
finance.yahoo.com - November 13 at 1:56 PM
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial ResultsApellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 2 at 8:13 AM
Apellis Pharmaceuticals (APLS) & Sobi Collaboration for Systemic Pegcetacoplan - SlideshowApellis Pharmaceuticals (APLS) & Sobi Collaboration for Systemic Pegcetacoplan - Slideshow
seekingalpha.com - October 30 at 11:02 PM
Apellis Pharmaceuticals (APLS) COVID-19 Study Updates - SlideshowApellis Pharmaceuticals (APLS) COVID-19 Study Updates - Slideshow
seekingalpha.com - October 30 at 11:02 PM
Biopharma startups sign drug licensing deals worth $2.5BBiopharma startups sign drug licensing deals worth $2.5B
bizjournals.com - October 27 at 2:43 PM
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
markets.businessinsider.com - October 19 at 7:42 AM
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 SeverityApellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
markets.businessinsider.com - October 15 at 8:09 AM
Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney WeekApellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
markets.businessinsider.com - October 9 at 12:41 PM
Apellis to present positive results in C3 Glomerulopathy at ASN Kidney WeekApellis to present positive results in C3 Glomerulopathy at ASN Kidney Week
seekingalpha.com - October 9 at 12:41 PM
Apellis initiates mid-stage pegcetacoplan studies in rare kidney and neurological diseasesApellis initiates mid-stage pegcetacoplan studies in rare kidney and neurological diseases
seekingalpha.com - October 5 at 8:27 AM
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet NeedApellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
markets.businessinsider.com - October 5 at 8:27 AM
Apellis initiates registrational Pegcetacoplan studies in rare kidney and neurological diseasesApellis initiates registrational Pegcetacoplan studies in rare kidney and neurological diseases
seekingalpha.com - October 5 at 8:27 AM
Apellis Pharmaceuticals to Present at Stifels 2020 Immunology and Inflammation Virtual SummitApellis Pharmaceuticals to Present at Stifel's 2020 Immunology and Inflammation Virtual Summit
benzinga.com - September 25 at 1:24 PM
Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual SummitApellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
markets.businessinsider.com - September 24 at 5:55 PM
Apellis Pharmaceuticals IncApellis Pharmaceuticals Inc
bloomberg.com - August 21 at 8:32 PM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.